Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REBECCA ARIELLE SHATSKY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1760778526
CMS profile
1153932
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$8,438.42

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,600.00 2
Honoraria $550.00 1
Long term medical supply or device loan $199.40 2
Food and Beverage $89.02 2

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REBECCA ARIELLE SHATSKY

NPI 1760778526 · CMS profile ID 1153932

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760778526?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REBECCA ARIELLE SHATSKY, NPI 1760778526, CMS profile ID 1153932. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760778526?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). REBECCA ARIELLE SHATSKY, NPI 1760778526, CMS profile ID 1153932. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760778526?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
REBECCA ARIELLE SHATSKY, NPI 1760778526, CMS profile ID 1153932, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1760778526?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $8,438.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $99.7012/15/2022 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894362183 CMS
AstraZeneca Pharmaceuticals LP $54.2012/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915460151 CMS
Novartis Pharmaceuticals Corporation $99.7011/18/2022 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894362179 CMS
Novartis Pharmaceuticals Corporation $34.8207/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894362175 CMS
Gilead Sciences, Inc. $6,100.0006/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929449639 CMS
Daiichi Sankyo Inc. $550.0004/12/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930794205 CMS
Janssen Research & Development, LLC $1,500.0001/31/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887130353 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $500.00 1
PY2020 $1,634.66 2
PY2021 $1,121.92 2
PY2022 $8,438.42 7
PY2023 $17,824.57 16
PY2024 $10,286.66 11
PY2025 $19,181.35 23

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $217,767.05 58
PY2024 Principal investigator $226,923.15 24
PY2023 Principal investigator $57,066.29 7
PY2022 Principal investigator $284,357.73 27
PY2021 Principal investigator $319,721.74 22
PY2020 Principal investigator $162,584.36 17
PY2019 Principal investigator $29,410.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722354
Principal investigator 1 PFIZER INC. $500.00 12/18/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228722404
Principal investigator 1 Stemline Therapeutics Inc. $1,995.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107383
Principal investigator 1 Stemline Therapeutics Inc. $4,681.60 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107389
Principal investigator 1 Stemline Therapeutics Inc. $5,320.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107396
Principal investigator 1 Stemline Therapeutics Inc. $2,194.50 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107403
Principal investigator 1 Stemline Therapeutics Inc. $14,523.60 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107409
Principal investigator 1 Stemline Therapeutics Inc. $14,630.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107415
Principal investigator 1 Stemline Therapeutics Inc. $798.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107419
Principal investigator 1 Stemline Therapeutics Inc. $1,170.40 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107426
Principal investigator 1 Stemline Therapeutics Inc. $2,660.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107432
Principal investigator 1 Stemline Therapeutics Inc. $3,724.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107438
Principal investigator 1 Stemline Therapeutics Inc. $3,325.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107446
Principal investigator 1 Stemline Therapeutics Inc. $1,729.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107450
Principal investigator 1 Stemline Therapeutics Inc. $425.60 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107454
Principal investigator 1 Stemline Therapeutics Inc. $1,596.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107460
Principal investigator 1 Stemline Therapeutics Inc. $6,118.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107466
Principal investigator 1 Stemline Therapeutics Inc. $2,660.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107472
Principal investigator 1 Stemline Therapeutics Inc. $8,312.50 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107480
Principal investigator 1 Stemline Therapeutics Inc. $4,655.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107486
Principal investigator 1 Stemline Therapeutics Inc. $1,596.00 09/17/2025 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244107493
Principal investigator 1 Stemline Therapeutics Inc. $70.00 09/01/2025 Non-covered Recipient Entity
UC San Diego Moores Cancer Center
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136446
Principal investigator 1 Stemline Therapeutics Inc. $91.15 07/17/2025 Non-covered Recipient Entity
UC San Diego Moores Cancer Center
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136442
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228724024
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784808
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784828
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785149
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785188
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785200
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785512
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228787195
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788250
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788366
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228788770
Principal investigator 1 PFIZER INC. $500.00 06/23/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789577
Principal investigator 1 Genentech, Inc. $2,195.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667841
Principal investigator 1 Genentech, Inc. $306.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667854
Principal investigator 1 Genentech, Inc. $399.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667856
Principal investigator 1 Genentech, Inc. $1,995.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667859
Principal investigator 1 Genentech, Inc. $665.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667862
Principal investigator 1 Genentech, Inc. $1,330.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667864
Principal investigator 1 Genentech, Inc. $5,719.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667874
Principal investigator 1 Genentech, Inc. $1,330.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667880
Principal investigator 1 Genentech, Inc. $3,325.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667887
Principal investigator 1 Genentech, Inc. $425.60 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667898
Principal investigator 1 Genentech, Inc. $8,313.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667901
Principal investigator 1 Genentech, Inc. $6,118.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667910
Principal investigator 1 Genentech, Inc. $13,300.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667913
Principal investigator 1 Genentech, Inc. $3,724.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667916
Principal investigator 1 Genentech, Inc. $5,320.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667919
Principal investigator 1 Genentech, Inc. $13,300.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667933
Principal investigator 1 Genentech, Inc. $1,729.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667938
Principal investigator 1 Genentech, Inc. $1,596.00 06/13/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) No dispute reported 06/30/2026 1211667943
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,402.10 03/28/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185546423
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228784825
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228785697
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228786158
Principal investigator 1 PFIZER INC. $500.00 03/12/2025 Non-covered Recipient Entity
Regents of the University of California
PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 No dispute reported 06/30/2026 1228789277